Freeport-McMoRan stock tumbles after Trump imposes copper tariffs
John Mazzola, Chief Operating Officer of Vicarious Surgical Inc. (NYSE:RBOT), recently sold 264 shares of the company’s Class A common stock. The sale, disclosed in a filing with the Securities and Exchange Commission, took place on March 3, 2025, at a weighted average price of $10.28 per share. The transaction generated approximately $2,713.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units granted on June 2, 2023. Following this transaction, Mazzola retains ownership of 9,498 shares of the company. With the company’s next earnings report due on March 17, InvestingPro subscribers can access detailed analysis and 12 additional ProTips about RBOT’s financial health.
Vicarious Surgical, headquartered in Waltham, Massachusetts, is engaged in developing innovative surgical technologies. The company maintains a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 7.44x, indicating solid short-term liquidity.
In other recent news, Vicarious Surgical Inc. announced that its Chief Operating Officer, John Mazzola, will retire on April 1, 2025, after a long career in the healthcare sector. His role will be taken over by Randy Clark, the current President of the company. Additionally, Vicarious Surgical has entered into a consulting agreement with its former Chief Financial Officer, William Kelly. Under this agreement, Kelly will provide advisory services from January 2, 2025, to December 31, 2028, starting with a monthly rate of $10,000 for the first six months. After this period, he will be compensated on an hourly basis. The company has also ensured that Kelly retains the vesting rights to his stock options and restricted stock units until June 30, 2025. These developments are part of Vicarious Surgical’s ongoing strategic initiatives as it continues to focus on innovation in the medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.